<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with no prior chemotherapy and with advanced and progressive follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FCL) or mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) were enrolled into a treatment protocol combining CHOP/rituximab-CHOP therapy with subsequent consolidation high-dose therapy (HDT) to evaluate the safety and feasibility of this treatment </plain></SENT>
<SENT sid="1" pm="."><plain>Overall, 15 patients were enrolled and 13 patients completed the entire treatment protocol without major toxicities or increased infectious complications </plain></SENT>
<SENT sid="2" pm="."><plain>One patient withdrew consent after achieving complete remission (CR) prior to HDT </plain></SENT>
<SENT sid="3" pm="."><plain>One patient was taken off study with signs of disease progression after induction treatment </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients showed stable engraftment after HDT </plain></SENT>
<SENT sid="5" pm="."><plain>Response rates appear to be favorable, indicating an additional effect of rituximab and HDT </plain></SENT>
<SENT sid="6" pm="."><plain>Overall, 12 of 13 patients achieved CR/CRu and one patient partial remission </plain></SENT>
<SENT sid="7" pm="."><plain>Follow-up of immune reconstitution displayed transient <z:hpo ids='HP_0004430'>severe combined immunodeficiency</z:hpo> with slow normalization of the cellular and humoral compartments without a significant increase of infectious complications </plain></SENT>
<SENT sid="8" pm="."><plain>Taken together, high-dose chemotherapy can be safely given following treatment with CHOP+rituximab </plain></SENT>
<SENT sid="9" pm="."><plain>Efficacy in this small cohort of patients was encouraging with sustained remissions in both FCL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> patients </plain></SENT>
<SENT sid="10" pm="."><plain>Upfront HDT should be considered as a therapeutic option especially in young and/or high-risk patients </plain></SENT>
</text></document>